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Brain metastases and primary CNS tumours 
Brain metastases are the most frequently occurring neurologic complications of cancer in 
adults, with 9 – 17% of all cancers resulting in brain metastasis and brain metastasis 
occurring in 8 – 14 per 100,000 in the general population [1].  Primary brain tumours, on the 
other hand, are relatively rare, and comprise about 1.4% of cancers [2]. Brain metastases are 
associated with a median survival times of about 3 – 25 months [3], and a 5 year survival rate 
of 1.8% [4]. Treatment modalities employed for brain metastases include: surgical resection, 
whole brain radiation therapy, radiosurgery and chemotherapy [5]. The choice of treatment 
would usually be based on several considerations. These include: histopathology of the 
primary tumour, status of systemic disease, patient’s performance status (general well being 
and lifestyle activity level), age of the patient, number and sites and precise location of the 

































































brain metastases (such as proximity to sites of vital brain function), co-existing morbidities, 
and symptoms [2,5].  
Glioblastoma multiforme (WHO Classification astrocytoma Grade IV), a metastatic primary 
brain tumour, accounts for 12 – 15% of all brain tumours [6] and is the most common 
primary brain tumour in adults [7].   Glioblastoma is an aggressive metastatic astrocytoma 
with a median survival of 14 months and less than 5% of patients survive for 3 years [8]. This 
tumour is difficult to diagnose early as the tumour is usually asymptomatic or presents with 
symptoms which are difficult to associate with GBM, e.g. symptoms associated with a high 
intracranial pressure (headaches, nausea, vomiting and cognitive impairment) [9].  A major 
contribution to the poor survival rates is the insufficient transport of therapeutic molecules 
across the blood brain barrier (BBB) [10]. The current standard of care comprises surgical 
resection to the maximum possible extent, followed by concurrent radio–chemotherapy and 
adjuvant chemotherapy with temozolomide [2]. This treatment regimen became the standard 
of care for newly diagnosed glioblastoma patients after the results of the 2004 European 
Organisation for Research and Treatment of Cancer 26981-22981/ National Cancer Institute 
of Canada Clinical Trials Group CE3 randomised phase III trial demonstrated a 20.7% 
improvement in the median survival as well as 27.2% two-year survival rates in glioblastoma 
patients, who had received post-surgical concomitant and adjuvant temozolomide (known as 
the Stupp regimen) compared to 10.9% two-year survival rates with post-surgical 
radiotherapy alone [11]. For recurrent glioblastoma on the other hand, there is currently no 
standard treatment regimen [12], and thus patients frequently receive investigational agents in 
clinical trials [13]. 
The Blood Brain Barrier (BBB) 
The treatment of brain tumours (or more generally, central nervous system (CNS) tumours) is 
particularly challenging, mainly because of their intracranial location [14].  Intracranial 

































































tumours are effectively “shielded” from the effects of most systemically administered 
cytotoxic agents. The brain parenchyma and most (but not all) intracranial tumours are 
protected by the intact blood brain barrier (BBB), which maintains the brain 
microenvironment by serving as a physical and metabolic barrier regulating the access of 
molecules to the brain [15]. The physical barrier is formed by the tight junctions  between the 
adjacent endothelial cells (which prevent blood-borne substances from crossing into the brain 
parenchyma), a lack of capillary fenestrations, very low pinocytotic activity and the 
metabolic barrier is formed by degradative enzymes, specialised transport receptors and 
endothelial cell efflux pumps [15].  
Other Brain Tumour Treatment Barriers 
Another barrier thought to restrict access of systemically administered therapeutic agents to 
tumour cells is the brain tumour-cell barrier (BTB, a barrier due to the efflux activity of 
tumour cells) [16]. Other challenges associated with effective brain tumour treatment are: 
dose limiting toxicity, mainly myelosuppression and tumour resistance to alkylating agents;  
the latter mediated mainly by the overexpression of O
6
-methylguanine-DNA-
methyltransferase (MGMT), a ubiquitous protein encoded by the MGMT gene [14]. 
Passive Targeting with Nanoparticles 
Nanoparticles have been used to passively target drugs to intracranial tumours, on 
intravenous injection, in order to enable delivery of therapeutics across the BBB to the brain, 
as there is evidence that nanoparticles are able to preferentially accumulate drug at tumour 
sites, when compared to the administration of drugs in solution [17].  Generally nanoparticles 
may be engineered to: a) enable tissue or organ specific transport of their drug payload, or b) 
enable the delivery of hydrophobic and metabolically labile drugs [18,19]. Thus, 
nanoparticles are an interesting platform to consider in drug development for brain tumour 
indications [19].  

































































Intravenously administered nanoparticles for delivery of therapeutic agents to brain tumours 
may theoretically exploit the enhanced permeability and retention (EPR) effect, whereby 
particles extravasate through a leaky tumour vasculature and achieve closer proximity to the 
tumour cells [20].  However for the EPR effect to be operational, the BBB must be 
compromised at the site of the intracranial tumour and while the breakdown of the BBB is 
diagnostic of a high grade glioma [21] most tumours are associated with an intact BBB [22] 
and direct evidence of nanoparticle accumulation within intracranial tumour cells is difficult 
to find. Early activity in this area focused on the delivery of P-gp efflux pump substrates to 
the brain in an attempt to circumvent the blood tumour-cell barrier. The P-gp substrate [23], 
doxorubicin,  when intravenously injected in poly(butylcyanoacrylate) nanoparticles, resulted 
in increased tumour tissue accumulation, in a mouse  C6 glioma rat model, when compared to 
healthy tissue and an attendant improvement in tumouricidal activity was observed with these 
nanoparticles when compared to the drug in solution [24]. Additionally, the formulation was 
also found to be less cardiotoxic.  This provides indirect evidence that nanoparticles are able 
to take advantage of a variation in the BBB at the tumour site.      
As well as the cyanoacrylates, other polymers have also demonstrated the tumour tissue drug 
accumulation phenomenon on intravenous injection. Doxorubicin loaded on to poloxamer 
188-coated poly-(lactic acid-co-glycolic acid) (PLGA) nanoparticles in a rat glioblastoma 
101/8 model resulted in superior tumouricidal activity, through the intravenous route, when 
compared to the drug in solution [25].  
Nanomedicines may also consist of more than one therapeutic for the treatment of brain 
tumours. For example, chitosan surface modified PLGA nanoparticles loaded with 
carmustine along with O
6
-benzylguanine (which depletes MGMT, thus improving the 
therapeutic efficacy of carmustine). On intravenous injection, this nanoparticle formulation 
yielded superior survival outcomes in F98 glioma-bearing rats compared to the 
administration of the two drugs separately in solution or to the nanoparticle containing 
carmustine alone [26].  
Nanoparticles may also work by simply increasing plasma exposure, which in turn increases 
brain exposure, while minimising exposure to areas of potential toxicity [27].  We have 
shown that lomustine loaded on to GCPQ (N-palmitoyl-N-monomethyl-N,N-dimethyl-
N,N,N-trimethyl-6-O-glycolchitosan) nanoparticles resulted in increased plasma and brain 
exposure, reduced liver and bone exposure and ultimately increased tumouricidal activity 

































































(survival and tumour size) in a U87MG intracranial tumour model, without increasing 
myelosuppression [27].    
Active Targeting with Nanoparticles 
Active targeting involves the use of carriers bearing various surface ligands to achieve either 
transport across an intact BBB, or alternatively, cell uptake following extravasation across a 
leaky BBB [28].  
Various across BBB transporters have been exploited for transport across an intact BBB, such 
as the transferrin receptor [29] and the GLUT receptor [30].  Transferrin – cyclo-[Arg-Gly-
Asp-d-Phe-Lys] -  c[RGDfK] paclitaxel micelles have been prepared and injected 
intravenously to a U87MG mouse model, with transferrin included to enable across BBB 
transport while c[RGDfK] was included to enable uptake by tumour cells [29]. This resulted 
in drug accumulation in the brain and a superior anti-glioma effect compared to  the 
commercial formulation, Taxol [29].  Others have utilised the T7 peptide (HAIYPRH) to 
target the endothelial cell transferrin receptor and achieve across BBB transport [31].  T7 
peptide modified core-shell nanoparticles (T7-LPC/siRNA) have been shown, on intravenous 
administration, to accumulate anti-epidermal growth factor receptor (anti-EGFR) siRNA in 
intracranial tumour tissue, down regulate EGFR and increase survival rates in a U87MG 
mouse tumour model, when compared to plain nanoparticles [31]. While the T7 peptide 
appears to achieve delivery across the BBB [31], efforts to improve cell uptake, once 
extravasation has taken place, have involved the use of dual targeting strategies, in which 
transport across the BBB is combined with a ligand promoting tumour cell uptake [32].  
Intravenously administered dual targeted doxorubicin liposomes comprising the TAT peptide 
(AYGRKKRRQRRR) for cellular uptake and the T7 peptide for across BBB transport 
resulted in increased delivery of doxorubicin to the brain glioma tissue in a C6 glioma mouse 
model and reduced delivery to the heart, which is relevant for the cardiotoxic [33] drug 
doxorubicin [32].   
Utilisation of the GLUT receptor to cross the BBB has been achieved by using 2-deoxy-D-
glucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) paclitaxel 
nanoparticles [30].  The 2-deoxy-D-glucose moiety was correlated with drug accumulation in 
the brain and these glucose-decorated nanoparticles produced superior survival in an RG2 
mouse glioma model, when compared to plain nanoparticles and Taxol [30]. 

































































While there is good preclinical evidence showing the efficacy of nanoparticles in rodent 
models of intracranial tumours, clinical evidence on the use of nanoparticles is harder to 
locate.  There are some reports of clinical trials in brain tumour patients with passively 
targeted nanoparticles (Table 1): e.g. NCT02340156, NCT02820454, NCT01266096, 
NCT03020017, NCT00734682 [34,35], however the efficacy of this nanoparticle approach in 
the clinic has not yet been reported.  
Table 1: Clinical studies on intravenously injected nanoparticles in brain cancer 
Study number Nanoparticle 
type 



























Phase I Ref. 35 

















































































Study number Nanoparticle 
type 
Drug  Indication Study Phase References 
(PET) scan tumours 






NCT00734682 Liposome CPT-11 Recurrent 
high-grade 
gliomas 
Phase I Ref. 35 
 
Theranostics 
Imaging agents and drugs transported by a single nanoparticle is another area of innovation 
that has been applied to the treatment of experimental brain tumours and these are known as 
theranostics [17,36]. Intravenously administered polymeric nanoparticles loaded with smaller 
iron oxide nanoparticles (for magnetic resonance imaging – MRI), surface decorated with a 
tumour vasculature targeting F3 peptide (a 31-amino acid sequence of the NH2-terminal 
fragment of human high-mobility group protein 2) and encapsulating photofrin for 
photodynamic therapy (PDT), were accumulated within the intracranial tumour in a 9L 
glioma rat model, following intravenous administration, as visualised using MRI [37].  This 
theranostic improved survival rates in this model following PDT when compared to plain 
nanoparticles in combination with PDT or photofrin alone in combination with PDT. Iron 
oxide as an MRI imaging agent is the contrast enhancement agent of choice with a number of 
theranostics.  The combination of a tumour homing peptide (CGKRK), which targets the 
tumour endothelial and tumour cells and specifically their mitochondria with a pro-apoptotic 
peptide (D[KLAKLAK]2) as the drug, when coupled to elongated iron oxide nanoparticles 
(nanoworms), as the MRI contrast agent, has been shown to  accumulate these targeted 
nanoworms in the tumour tissue following intravenous injection [38].  The targeted 
nanoworms were significantly more effective than non-targeted nanoworms in a lentiviral (H-
RasV12-shp53) induced mouse brain tumour model.    
An alternative method of labelling nanoparticles for imaging in a theranostic platform 
involves the use of porphyrin for near infrared imaging and as such 30 nm porphyrin-lipid 

































































apolipoprotein E3 (apoE3) lipid nanoparticles (pyE-LNs) with intrinsic imaging properties 
via the porphyrin lipid have been studied [39].  Across BBB delivery and tumour cell uptake 
properties were achieved using ApoE as ApoE is taken up by the low-density lipoprotein 
receptor (LDLR) on brain endothelial cells and tumour cells, where in the latter case, the 
LDLR receptor is upregulated [39].  After intravenous administration to a U87 Green 
Fluorescent Protein (GFP) mouse model, the particles were found to accumulate within brain 
tumour tissue.  
These image competent nanotherapeutics may prove interesting in the treatment of diffuse 
brain metastasis in multiple brain regions. 
Conclusions 
Glioblastoma and brain metastasis are still areas of unmet medical need and several 
nanoparticle formulations are showing promise in glioblastoma rodent models of the disease 
with a few even transitioning to clinical testing.   The leaky vasculature in brain tumours has 
been exploited to concentrate drug-laden nanoparticles at the tumour site, following 
intravenous injection.  Additionally, various across BBB transport and cell uptake ligands 
have been employed within a single nanoparticle to enable drug to be concentrated in tumour 
cells in the presence of an intact BBB, following intravenous injection.  These combined 
systems are known as dual targeting systems.  Recent studies have introduced MRI and near 
infrared imaging to drug loaded nanoparticles, enabling targeting to be imaged with these 
new theranostics.  The transferrin receptor has been widely exploited for across BBB 
transport, in these experimental studies, and a number of cell uptake ligands employed in the 
dual targeting approaches.   It remains to be seen if the promising rodent data is indeed 
translatable to the clinical situation and attention will need to be turned to the issue of 
manufacturability if the ligand targeting systems are to transition into clinical products.  
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Table 1: Clinical studies on intravenously injected nanoparticles in brain cancer 
Study number Nanoparticle 
type 
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NCT00734682 Liposome CPT-11 Recurrent Phase I Ref. 35 
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Brain tumour, nanomedicine, nanoparticle, theranostic, glioblastoma, doxorubicin, paclitaxel 
Brain metastases and primary CNS tumours 
Brain metastases are the most frequently occurring neurologic complications of cancer in 
adults, with 9 – 17% of all cancers resulting in brain metastasis and brain metastasis 
occurring in 8 – 14 per 100,000 in the general population [1].  Primary brain tumours, on the 
other hand, are relatively rare, and comprise about 1.4% of cancers [2]. Brain metastases are 
associated with a median survival times of about 3 – 25 months [3], and a 5 year survival rate 
of 1.8% [4]. Treatment modalities employed for brain metastases include: surgical resection, 
whole brain radiation therapy, radiosurgery and chemotherapy [5]. The choice of treatment 
would usually be based on several considerations. These include: histopathology of the 
primary tumour, status of systemic disease, patient’s performance status (general well being 
and lifestyle activity level), age of the patient, number and sites and precise location of the 
brain metastases (such as proximity to sites of vital brain function), co-existing morbidities, 
and symptoms [2,5].  
Glioblastoma multiforme (WHO Classification astrocytoma Grade IV), a metastatic primary 
brain tumour, accounts for 12 – 15% of all brain tumours [6] and is the most common 
primary brain tumour in adults [7].   Glioblastoma is an aggressive metastatic astrocytoma 
with a median survival of 14 months and less than 5% of patients survive for 3 years [8]. This 
tumour is difficult to diagnose early as the tumour is usually asymptomatic or presents with 
symptoms which are difficult to associate with GBM, e.g. symptoms associated with a high 
intracranial pressure (headaches, nausea, vomiting and cognitive impairment) [9].  A major 
contribution to the poor survival rates is the insufficient transport of therapeutic molecules 
across the blood brain barrier (BBB) [10]. The current standard of care comprises surgical 

































































resection to the maximum possible extent, followed by concurrent radio–chemotherapy and 
adjuvant chemotherapy with temozolomide [2]. This treatment regimen became the standard 
of care for newly diagnosed glioblastoma patients after the results of the 2004 European 
Organisation for Research and Treatment of Cancer 26981-22981/ National Cancer Institute 
of Canada Clinical Trials Group CE3 randomised phase III trial demonstrated a 20.7% 
improvement in the median survival as well as 27.2% two-year survival rates in glioblastoma 
patients, who had received post-surgical concomitant and adjuvant temozolomide (known as 
the Stupp regimen) compared to 10.9% two-year survival rates with post-surgical 
radiotherapy alone [11]. For recurrent glioblastoma on the other hand, there is currently no 
standard treatment regimen [12], and thus patients frequently receive investigational agents in 
clinical trials [13]. 
The Blood Brain Barrier (BBB) 
The treatment of brain tumours (or more generally, central nervous system (CNS) tumours) is 
particularly challenging, mainly because of their intracranial location [14].  Intracranial 
tumours are effectively “shielded” from the effects of most systemically administered 
cytotoxic agents. The brain parenchyma and most (but not all) intracranial tumours are 
protected by the intact blood brain barrier (BBB), which maintains the brain 
microenvironment by serving as a physical and metabolic barrier regulating the access of 
molecules to the brain [15]. The physical barrier is formed by the tight junctions  between the 
adjacent endothelial cells (which prevent blood-borne substances from crossing into the brain 
parenchyma), a lack of capillary fenestrations, very low pinocytotic activity and the 
metabolic barrier is formed by degradative enzymes, specialised transport receptors and 
endothelial cell efflux pumps [15].  

































































Other Brain Tumour Treatment Barriers 
Another barrier thought to restrict access of systemically administered therapeutic agents to 
tumour cells is the brain tumour-cell barrier (BTB, a barrier due to the efflux activity of 
tumour cells) [16]. Other challenges associated with effective brain tumour treatment are: 
dose limiting toxicity, mainly myelosuppression and tumour resistance to alkylating agents;  
the latter mediated mainly by the overexpression of O
6
-methylguanine-DNA-
methyltransferase (MGMT), a ubiquitous protein encoded by the MGMT gene [14]. 
Passive Targeting with Nanoparticles 
Nanoparticles have been used to passively target drugs to intracranial tumours, on 
intravenous injection, in order to enable delivery of therapeutics across the BBB to the brain, 
as there is evidence that nanoparticles are able to preferentially accumulate drug at tumour 
sites, when compared to the administration of drugs in solution [17].  Generally nanoparticles 
may be engineered to: a) enable tissue or organ specific transport of their drug payload, or b) 
enable the delivery of hydrophobic and metabolically labile drugs [18,19]. Thus, 
nanoparticles are an interesting platform to consider in drug development for brain tumour 
indications [19].  
Intravenously administered nanoparticles for delivery of therapeutic agents to brain tumours 
may theoretically exploit the enhanced permeability and retention (EPR) effect, whereby 
particles extravasate through a leaky tumour vasculature and achieve closer proximity to the 
tumour cells [20].  However for the EPR effect to be operational, the BBB must be 
compromised at the site of the intracranial tumour and while the breakdown of the BBB is 
diagnostic of a high grade glioma [21] most tumours are associated with an intact BBB [22] 
and direct evidence of nanoparticle accumulation within intracranial tumour cells is difficult 
to find. Early activity in this area focused on the delivery of P-gp efflux pump substrates to 
the brain in an attempt to circumvent the blood tumour-cell barrier. The P-gp substrate [23], 
doxorubicin,  when intravenously injected in poly(butylcyanoacrylate) nanoparticles, resulted 
in increased tumour tissue accumulation, in a mouse  C6 glioma rat model, when compared to 
healthy tissue and an attendant improvement in tumouricidal activity was observed with these 
nanoparticles when compared to the drug in solution [24]. Additionally, the formulation was 

































































also found to be less cardiotoxic.  This provides indirect evidence that nanoparticles are able 
to take advantage of a variation in the BBB at the tumour site.      
As well as the cyanoacrylates, other polymers have also demonstrated the tumour tissue drug 
accumulation phenomenon on intravenous injection. Doxorubicin loaded on to poloxamer 
188-coated poly-(lactic acid-co-glycolic acid) (PLGA) nanoparticles in a rat glioblastoma 
101/8 model resulted in superior tumouricidal activity, through the intravenous route, when 
compared to the drug in solution [25].  
Nanomedicines may also consist of more than one therapeutic for the treatment of brain 
tumours. For example, chitosan surface modified PLGA nanoparticles loaded with 
carmustine along with O
6
-benzylguanine (which depletes MGMT, thus improving the 
therapeutic efficacy of carmustine). On intravenous injection, this nanoparticle formulation 
yielded superior survival outcomes in F98 glioma-bearing rats compared to the 
administration of the two drugs separately in solution or to the nanoparticle containing 
carmustine alone [26].  
Nanoparticles may also work by simply increasing plasma exposure, which in turn increases 
brain exposure, while minimising exposure to areas of potential toxicity [27].  We have 
shown that lomustine loaded on to GCPQ (N-palmitoyl-N-monomethyl-N,N-dimethyl-
N,N,N-trimethyl-6-O-glycolchitosan) nanoparticles resulted in increased plasma and brain 
exposure, reduced liver and bone exposure and ultimately increased tumouricidal activity 
(survival and tumour size) in a U87MG intracranial tumour model, without increasing 
myelosuppression [27].    
Active Targeting with Nanoparticles 
Active targeting involves the use of carriers bearing various surface ligands to achieve either 
transport across an intact BBB, or alternatively, cell uptake following extravasation across a 
leaky BBB [28].  
Various across BBB transporters have been exploited for transport across an intact BBB, such 
as the transferrin receptor [29] and the GLUT receptor [30].  Transferrin – cyclo-[Arg-Gly-
Asp-d-Phe-Lys] -  c[RGDfK] paclitaxel micelles have been prepared and injected 
intravenously to a U87MG mouse model, with transferrin included to enable across BBB 
transport while c[RGDfK] was included to enable uptake by tumour cells [29]. This resulted 
in drug accumulation in the brain and a superior anti-glioma effect compared to  the 
commercial formulation, Taxol [29].  Others have utilised the T7 peptide (HAIYPRH) to 

































































target the endothelial cell transferrin receptor and achieve across BBB transport [31].  T7 
peptide modified core-shell nanoparticles (T7-LPC/siRNA) have been shown, on intravenous 
administration, to accumulate anti-epidermal growth factor receptor (anti-EGFR) siRNA in 
intracranial tumour tissue, down regulate EGFR and increase survival rates in a U87MG 
mouse tumour model, when compared to plain nanoparticles [31]. While the T7 peptide 
appears to achieve delivery across the BBB [31], efforts to improve cell uptake, once 
extravasation has taken place, have involved the use of dual targeting strategies, in which 
transport across the BBB is combined with a ligand promoting tumour cell uptake [32].  
Intravenously administered dual targeted doxorubicin liposomes comprising the TAT peptide 
(AYGRKKRRQRRR) for cellular uptake and the T7 peptide for across BBB transport 
resulted in increased delivery of doxorubicin to the brain glioma tissue in a C6 glioma mouse 
model and reduced delivery to the heart, which is relevant for the cardiotoxic [33] drug 
doxorubicin [32].   
Utilisation of the GLUT receptor to cross the BBB has been achieved by using 2-deoxy-D-
glucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) paclitaxel 
nanoparticles [30].  The 2-deoxy-D-glucose moiety was correlated with drug accumulation in 
the brain and these glucose-decorated nanoparticles produced superior survival in an RG2 
mouse glioma model, when compared to plain nanoparticles and Taxol [30]. 
While there is good preclinical evidence showing the efficacy of nanoparticles in rodent 
models of intracranial tumours, clinical evidence on the use of nanoparticles is harder to 
locate.  There are some reports of clinical trials in brain tumour patients with passively 
targeted nanoparticles (Table 1): e.g. NCT02340156, NCT02820454, NCT01266096, 
NCT03020017, NCT00734682 [34,35], however the efficacy of this nanoparticle approach in 
the clinic has not yet been reported.  
Table 1: Clinical studies on intravenously injected nanoparticles in brain cancer 
Study number Nanoparticle 
type 










Phase II Ref. 35 

































































Study number Nanoparticle 
type 

















Phase I Ref. 35 
























NCT00734682 Liposome CPT-11 Recurrent 
high-grade 
gliomas 
Phase I Ref. 35 
 


































































Imaging agents and drugs transported by a single nanoparticle is another area of innovation 
that has been applied to the treatment of experimental brain tumours and these are known as 
theranostics [17,36]. Intravenously administered polymeric nanoparticles loaded with smaller 
iron oxide nanoparticles (for magnetic resonance imaging – MRI), surface decorated with a 
tumour vasculature targeting F3 peptide (a 31-amino acid sequence of the NH2-terminal 
fragment of human high-mobility group protein 2) and encapsulating photofrin for 
photodynamic therapy (PDT), were accumulated within the intracranial tumour in a 9L 
glioma rat model, following intravenous administration, as visualised using MRI [37].  This 
theranostic improved survival rates in this model following PDT when compared to plain 
nanoparticles in combination with PDT or photofrin alone in combination with PDT. Iron 
oxide as an MRI imaging agent is the contrast enhancement agent of choice with a number of 
theranostics.  The combination of a tumour homing peptide (CGKRK), which targets the 
tumour endothelial and tumour cells and specifically their mitochondria with a pro-apoptotic 
peptide (D[KLAKLAK]2) as the drug, when coupled to elongated iron oxide nanoparticles 
(nanoworms), as the MRI contrast agent, has been shown to  accumulate these targeted 
nanoworms in the tumour tissue following intravenous injection [38].  The targeted 
nanoworms were significantly more effective than non-targeted nanoworms in a lentiviral (H-
RasV12-shp53) induced mouse brain tumour model.    
An alternative method of labelling nanoparticles for imaging in a theranostic platform 
involves the use of porphyrin for near infrared imaging and as such 30 nm porphyrin-lipid 
apolipoprotein E3 (apoE3) lipid nanoparticles (pyE-LNs) with intrinsic imaging properties 
via the porphyrin lipid have been studied [39].  Across BBB delivery and tumour cell uptake 
properties were achieved using ApoE as ApoE is taken up by the low-density lipoprotein 
receptor (LDLR) on brain endothelial cells and tumour cells, where in the latter case, the 
LDLR receptor is upregulated [39].  After intravenous administration to a U87 Green 
Fluorescent Protein (GFP) mouse model, the particles were found to accumulate within brain 
tumour tissue.  
These image competent nanotherapeutics may prove interesting in the treatment of diffuse 
brain metastasis in multiple brain regions. 


































































Glioblastoma and brain metastasis are still areas of unmet medical need and several 
nanoparticle formulations are showing promise in glioblastoma rodent models of the disease 
with a few even transitioning to clinical testing.   The leaky vasculature in brain tumours has 
been exploited to concentrate drug-laden nanoparticles at the tumour site, following 
intravenous injection.  Additionally, various across BBB transport and cell uptake ligands 
have been employed within a single nanoparticle to enable drug to be concentrated in tumour 
cells in the presence of an intact BBB, following intravenous injection.  These combined 
systems are known as dual targeting systems.  Recent studies have introduced MRI and near 
infrared imaging to drug loaded nanoparticles, enabling targeting to be imaged with these 
new theranostics.  The transferrin receptor has been widely exploited for across BBB 
transport, in these experimental studies, and a number of cell uptake ligands employed in the 
dual targeting approaches.   It remains to be seen if the promising rodent data is indeed 
translatable to the clinical situation and attention will need to be turned to the issue of 
manufacturability if the ligand targeting systems are to transition into clinical products.  
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